Johns Hopkins ABX Guide
Molnupiravir
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
The FDA issued an Emergency Use Authorization (EUA) for the emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 disease in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.
- Risk for progression includes: age > 60 years, diabetes, obesity (BMI ≥ 30), chronic kidney disease, serious heart conditions, chronic obstructive pulmonary disease, or active cancer.
- Authorized for treatment within the first 5d of symptomatic COVID-19 illness.
Molnupiravir is NOT authorized for:
- Patients < 18 years of age
- Patients requiring hospitalization for the management of COVID-19 disease (benefit has not been observed in patients beginning treatment after hospitalization)
- Use longer than 5 consecutive days
- Pre-exposure or post-exposure prophylaxis for the prevention of COVID-19 disease
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
The FDA issued an Emergency Use Authorization (EUA) for the emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 disease in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.
- Risk for progression includes: age > 60 years, diabetes, obesity (BMI ≥ 30), chronic kidney disease, serious heart conditions, chronic obstructive pulmonary disease, or active cancer.
- Authorized for treatment within the first 5d of symptomatic COVID-19 illness.
Molnupiravir is NOT authorized for:
- Patients < 18 years of age
- Patients requiring hospitalization for the management of COVID-19 disease (benefit has not been observed in patients beginning treatment after hospitalization)
- Use longer than 5 consecutive days
- Pre-exposure or post-exposure prophylaxis for the prevention of COVID-19 disease
There's more to see -- the rest of this entry is available only to subscribers.
